Guerbet (GBT) a global leader in medical imaging, will host an on-demand session in the Innovation Theater during RSNA 2020.
WHEN: The program will be available at the above links until April 2021
WHAT: The number of pre-biopsy prostate MRIs has increased considerably in the last decade, yielding a higher number of prostate volumes to analyze and limited number of prostate-expert radiologists. Presented by Dr. Joseph Stancanello, Director of MRI Research, Guerbet Europe, the session will explore how artificial intelligence can increase workflow productivity, raise non-prostate-expert radiologists to the level of expert and share how Guerbet is addressing challenges associated with prostate MRIs with its own dedicated AI research team.
Guerbet is a leader in medical imaging worldwide, offering a wide range of pharmaceutical products, medical devices, digital and AI solutions for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. A pioneer since more than 90 years in the field of contrast media with over 2,800 people globally, Guerbet is continuously innovating with 9% of revenue dedicated to Research & Development and four centers in France, Israel and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €817 million in revenue in 2019. For more information about Guerbet, please visit www.guerbet.com.